Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

JTT-851

DRUG

Glimepiride

Encapsulated Glimepiride tablets

DRUG

Placebo for Active

DRUG

Placebo for comparator

Trial Locations (79)

Unknown

Birmingham

Dothan

Huntsville

Montgomery

Muscle Shoals

Glendale

Tucson

Little Rock

Artesia

Beverly Hills

Buena Park

Chino

Garden Grove

Lincoln

Lomita

Los Angeles

Newport Beach

North Hollywood

Paramount

Sacramento

Spring Valley

Walnut Creek

Denver

Cooper City

Fort Lauderdale

Hialeah

Kissimee

Miami

Miramar

Ocala

Orlando

Ormond Beach

Pembroke Pines

Port Orange

Tampa

Columbus

Marietta

Nampa

Chicago

Evanston

Indianapolis

Wichita

Lake Charles

New Orleans

Oxon Hill

Olive Branch

Las Vegas

Berlin

Mine Hill

Glen Falls

Greensboro

Cincinnati

Kettering

Marion

Munroe Falls

Wadsworth

Norman

Oklahoma City

Eugene

Portland

Lansdale

Columbia

Greer

Carrollton

Corpus Christi

Dallas

Houston

Plano

San Antonio

Sugarland

Tomball

Murray

Orem

Salt Lake City

Burke

Manassas

Norfolk

Suffolk

Madison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Akros Pharma Inc.

INDUSTRY

NCT01699737 - Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter